Annuncio • May 19

Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals, Inc. reported topline results for RSVP, its Phase 2b study evaluating EDP-938, a potent N-protein inhibitor, in otherwise healthy adults with community-acquired RSV. In this low-risk patient population which had mild, self-resolving upper respiratory tract infection, EDP-938 did not meet the primary endpoint of reduction in total symptom score compared to placebo, or the secondary antiviral endpoints. However, a statistically significant difference in the number of subjects achieving undetectable RSV RNA at the end of treatment at Day 5 was observed with EDP-938 compared to placebo (p=0.033). Further, EDP-938 demonstrated a favorable safety profile, consistent with that observed in approximately 500 subjects exposed to date. Enanta continues to evaluate EDP-938 in high-risk populations in ongoing and planned clinical studies, including pediatric patients, adult hematopoietic cell transplant recipients, and a high-risk adult population, all of which have the most significant unmet need. RSVP was a Phase 2b, randomized, double-blind, multicenter, placebo-controlled study in ambulatory adults with or without comorbidities aged 18 to 75 years with confirmed RSV infection within 48 hours of symptom onset. Patients were randomized 1:1 to receive once-daily 800 mg EDP-938 or placebo for 5 days and followed until Day 14. The primary objective of the study was to evaluate the effect of EDP-938 on progression of RSV infection by assessment of clinical symptoms measured over the 14-day study period. The secondary objectives evaluated the antiviral efficacy, safety, and pharmacokinetics of EDP-938. A total of 81 patients were randomized and dosed and included in the intent-to-treat (ITT) analysis. The modified ITT efficacy analysis included only the 66 patients (33 in each group) that were subsequently confirmed to be RSV positive using a central RT-PCR test. Demographics and baseline characteristics were well balanced between the two arms, except for the median RSV viral load (5.9 and 7.1 log10 copies/mL, in EDP-938 and placebo, respectively). Overall, most of the patients were female, White, non-Hispanic, young (median age approximately 50 years old) and had a normal frailty scale score, consistent with a healthy population as per the eligibility criteria of the study. Only eight patients were 65 years or older (n=3 in EDP-938, n=5 in placebo), and a total of seven patients (n=4 in EDP-938, n=3 in placebo) had stable asthma and/or chronic obstructive pulmonary disease (COPD), at entry. The primary endpoint, total symptom score (TSS) area under the curve (AUC) from Day 1 through Day 14, was not met. The AUC for the mean total symptom score (days x score) was not statistically different between the two groups (p=0.256). Although, the secondary antiviral endpoints were not met, a trend in favor of EDP-938 was observed with regard to the percentage of subjects achieving undetectable RSV RNA, with a statistically significant difference observed at the end of treatment at Day 5 (p=0.033). A total of 11 (27%) patients in both the EDP-938 and placebo arms reported treatment-emergent-adverse events. Most of the adverse events (AEs) were mild and not related to study drug. There were no severe or serious AEs, and no discontinuations due to AEs. In the study, the observed safety profile was consistent with previous clinical studies. Good EDP-938 exposures were achieved and were consistent with those observed in treated subjects in previous studies. Data from RSVP will be presented at a future medical meeting or in a peer-reviewed publication. Recruitment is ongoing for RSVPEDs, a Phase 2 randomized, double-blind, placebo-controlled study in hospitalized and non-hospitalized pediatric RSV patients, and RSVTx, a Phase 2b, randomized, double-blind, placebo-controlled study in adult hematopoietic cell transplant recipients with acute RSV infection and symptoms of upper respiratory tract infection. The company expects these studies to continue into 2023. Further, the company plans to initiate an additional Phase 2b study in a high-risk adult population, including the elderly and/or those with asthma, COPD, or congestive heart failure, by year-end. Finally, Enanta is on track to initiate a Phase 1 study for EDP-323, a novel, oral, direct-acting antiviral selectively targeting the RSV L-protein, in the second half of 2022. EDP-323 has shown sub-nanomolar potency against RSV-A and RSV-B in vitro and is not expected to have cross resistance to other classes of inhibitors. EDP-323 could be used as a monotherapy or in combination with other RSV mechanisms, such as EDP-938, to potentially broaden the addressable patient populations or their treatment windows. EDP-938, Enanta’s lead N-protein inhibitor, is being developed for the treatment of RSV infection, and has been granted Fast Track designation by the U.S. Food and Drug Administration. EDP-938 is a nanomolar inhibitor of both RSV-A and RSV-B activity. EDP-938 is differentiated from RSV fusion inhibitors as the N-protein inhibitor targets the virus’ replication machinery and has demonstrated a high barrier to resistance in vitro. In preclinical studies, EDP-938 maintained antiviral potency across all clinical isolates tested and was active against viral variants resistant to other mechanisms. EDP-938 demonstrated a favorable safety, pharmacokinetic and drug-drug interaction profile in an extensive Phase 1 program. In a Phase 2 challenge study, EDP-938 achieved highly statistically significant (p<0.001) reductions in RSV viral load and clinical symptoms compared to placebo, and was safe and well-tolerated with infrequent AEs. EDP-938 is currently being evaluated in RSVPEDs, a Phase 2 study in pediatric RSV patients, and RSVTx, a Phase 2b study in adult hematopoietic cell transplant recipients with RSV. RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under one year of age in the U.S. and a significant cause of respiratory illness in older adults and immunocompromised individuals.1 According to the Centers for Disease Control and Prevention, virtually all children in the United States get an RSV infection by the time they are two years old and one to two out of every 100 children younger than six months of age with RSV infection may need to be hospitalized.2 Globally, there are an estimated 33 million cases of RSV annually in children less than five years of age, with about 3 million hospitalized and up to approximately 120,000 dying each year from complications associated with the infection.3 RSV represents a significant health threat for adults older than 65 years of age, with an estimated 177,000 hospitalizations and 14,000 deaths associated with RSV infections annually in the United States.

Biotechs crescita degli utili	23.7%
Tasso di crescita dei ricavi	19.5%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	06 Jul 2026

Data	Ricavi	Utili	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
9/30/2028	99	-66	N/A	-117	3
9/30/2027	67	-57	-28	-44	5
9/30/2026	66	-59	-42	29	4
3/31/2026	69	-62	-10	-8	N/A
12/31/2025	67	-72	-18	-14	N/A
9/30/2025	65	-82	-32	-19	N/A
6/30/2025	65	-92	-44	-23	N/A
3/31/2025	64	-96	-82	-55	N/A
12/31/2024	67	-105	-96	-71	N/A
9/30/2024	68	-116	-97	-79	N/A
6/30/2024	72	-115	-100	-90	N/A
3/31/2024	73	-132	-113	-107	N/A
12/31/2023	74	-138	-99	-93	N/A
9/30/2023	79	-134	-112	-103	N/A
6/30/2023	81	-132	-106	-97	N/A
3/31/2023	81	-125	-102	-95	N/A
12/31/2022	82	-121	-112	-107	N/A
9/30/2022	86	-122	-87	-85	N/A
6/30/2022	89	-120	-91	-90	N/A
3/31/2022	92	-112	-91	-90	N/A
12/31/2021	93	-101	-69	-68	N/A
9/30/2021	97	-79	-71	-70	N/A
6/30/2021	97	-84	-65	-64	N/A
3/31/2021	94	-74	-40	-39	N/A
12/31/2020	102	-58	-21	-20	N/A
9/30/2020	122	-36	6	7	N/A
6/30/2020	150	2	30	31	N/A
3/31/2020	176	24	35	38	N/A
12/31/2019	188	34	N/A	54	N/A
9/30/2019	205	46	N/A	71	N/A
6/30/2019	221	65	N/A	91	N/A
3/31/2019	234	78	N/A	93	N/A
12/31/2018	238	86	N/A	55	N/A
9/30/2018	207	72	N/A	29	N/A
6/30/2018	215	81	N/A	58	N/A
3/31/2018	166	52	N/A	49	N/A
12/31/2017	131	34	N/A	54	N/A
9/30/2017	103	18	N/A	53	N/A
6/30/2017	40	-21	N/A	-7	N/A
3/31/2017	46	-13	N/A	-4	N/A
12/31/2016	50	-10	N/A	9	N/A
9/30/2016	88	22	N/A	36	N/A
6/30/2016	90	29	N/A	36	N/A
3/31/2016	87	33	N/A	23	N/A
12/31/2015	132	63	N/A	112	N/A
9/30/2015	161	79	N/A	77	N/A

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/08/02 22:58
Prezzo dell'azione a fine giornata	2026/07/31 00:00
Utili	2026/03/31
Utili annuali	2025/09/30

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

Analista	Istituzione
Brian Skorney	Baird
Geoffrey Meacham	Barclays
Patrick Trucchio	Berenberg

Enanta Pharmaceuticals Crescita futura

Criteri Future verificati 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

New minor risk - Share price stability

Enanta Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Enanta Pharmaceuticals Advances Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus

Insufficient new directors

Enanta Pharmaceuticals, Inc. to Report Q3, 2026 Results on Aug 10, 2026

Enanta Pharmaceuticals Inc Announces First Participant Dosed in Phase 1 Clinical Trial of Edp-978

Enanta Pharmaceuticals, Inc. to Report Q2, 2026 Results on May 11, 2026

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 11, 2026

Enanta Pharmaceuticals, Inc. Provides Update on Its Research and Development Programs

Enanta Pharmaceuticals, Inc. to Report Q1, 2026 Results on Feb 09, 2026

Enanta Pharmaceuticals, Inc. Presents New Data for Zelicapavir, its N-Protein Inhibitor and EDP-323, L-Protein Inhibitor

Enanta Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $65 million.

Enanta Pharmaceuticals Reports Positive Topline Results from Its Phase 2B Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus in High-Risk Adults

Enanta Pharmaceuticals, Inc. Announces Demise of Paul J. Mellett Jr, Chief Financial and Administrative Officer

Enanta Pharmaceuticals, Inc. Announces Executive Changes on August 26, 2025

Enanta Pharmaceuticals, Inc. to Report Q4, 2025 Results on Nov 17, 2025

Enanta Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Label Expansion for MAVYRET (Glecaprevir/Pibrentasvir), Oral Pangenotypic Direct Acting Antiviral (DAA) Therapy

Enanta Pharmaceuticals, Inc. to Report Q3, 2025 Results on Aug 11, 2025

Enanta Pharmaceuticals, Inc. to Report Q2, 2025 Results on May 12, 2025

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 13, 2025

Enanta Pharmaceuticals Announces Positive Topline Results from First-In-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: US$1.07 loss per share (vs US$1.86 loss in 3Q 2023)

Enanta Pharmaceuticals, Inc. to Report Q4, 2024 Results on Nov 25, 2024

Enanta Pharmaceuticals, Inc. to Report Q3, 2024 Results on Aug 05, 2024

Second quarter 2024 earnings released: US$1.47 loss per share (vs US$1.79 loss in 2Q 2023)

Enanta Pharmaceuticals, Inc. to Report Q2, 2024 Results on May 06, 2024

Enanta Pharmaceuticals, Inc. Appoints Matthew P. Kowalsky as Chief Legal Officer

First quarter 2024 earnings released: US$1.58 loss per share (vs US$1.39 loss in 1Q 2023)

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 06, 2024

Enanta Pharmaceuticals, Inc. Announces Retirement of Nathaniel S. Gardiner as Senior Vice President and General Counsel, Effective on or Before March 31, 2024

Independent Director recently sold €129k worth of stock

President recently sold €65k worth of stock

Full year 2023 earnings released: US$6.38 loss per share (vs US$5.91 loss in FY 2022)

Enanta Pharmaceuticals, Inc. to Report Q1, 2024 Results on Feb 07, 2024

New major risk - Share price stability

New minor risk - Profitability

Third quarter 2023 earnings released: US$1.86 loss per share (vs US$1.53 loss in 3Q 2022)

Enanta Pharmaceuticals, Inc. to Report Q4, 2023 Results on Nov 20, 2023

New major risk - Share price stability

Insufficient new directors

Enanta Pharmaceuticals, Inc. Announces Positive Data from A Phase 1 Clinical Study of Edp-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus

Second quarter 2023 earnings released: US$1.79 loss per share (vs US$1.64 loss in 2Q 2022)

Enanta Pharmaceuticals, Inc. to Report Q3, 2023 Results on Aug 07, 2023

First quarter 2023 earnings released: US$1.39 loss per share (vs US$1.48 loss in 1Q 2022)

Enanta Pharmaceuticals, Inc. to Report Q2, 2023 Results on May 08, 2023

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 02, 2023

Full year 2022 earnings released: US$5.91 loss per share (vs US$3.92 loss in FY 2021)

Enanta Pharmaceuticals, Inc. to Report Q1, 2023 Results on Feb 07, 2023

Enanta Pharmaceuticals, Inc. Initiates Sprint, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19

Enanta Pharmaceuticals, Inc. Announces New Preclinical Data Supporting the Potential of EDP-235 for the Treatment of COVID-19

Enanta Pharmaceuticals, Inc. Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus

Enanta Pharmaceuticals, Inc. Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus

Enanta Pharmaceuticals, Inc. to Report Q4, 2022 Results on Nov 21, 2022

Enanta Pharmaceuticals, Inc. Announces Appointment of Scott T. Rottinghaus to the Position of Senior Vice President and Chief Medical Officer

Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.19 loss in 3Q 2021)

Enanta Pharmaceuticals, Inc. to Report Q3, 2022 Results on Aug 08, 2022

Enanta Pharmaceuticals, Inc Announces Positive Data from A Phase 1 Clinical Study of EDP-235, Its Oral 3Cl Protease Inhibitor Designed for the Treatment of Covid-19

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from Russell 2000 Growth-Defensive Index

Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)

Second quarter 2022 earnings released: US$1.64 loss per share (vs US$1.09 loss in 2Q 2021)

Enanta Pharmaceuticals, Inc. to Report Q2, 2022 Results on May 09, 2022

Enanta Pharmaceuticals, Inc. Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

Enanta Pharmaceuticals, Inc. Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

Enanta Pharmaceuticals, Inc. announced delayed 10-Q filing

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Enanta Pharmaceuticals, Inc. to Report Q1, 2022 Results on Feb 08, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Director Yujiro Hata has joined 3rd company board

Enanta Pharmaceuticals, Inc. Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer

Third quarter 2021 earnings released: US$1.19 loss per share (vs US$0.71 loss in 3Q 2020)

Enanta Pharmaceuticals Presents New Data for EDP-721, an Oral Hepatitis B Virus RNA Destabilizer, at the European Association for the Study of the Liver (EASL) International Liver Congress™

Enanta Pharmaceuticals, Inc. Reports Positive Data from Phase 1b Study of EDP-514, a Hepatitis B Virus (HBV) Core Inhibitor, in Viremic Chronic HBV Patients

Second quarter 2021 earnings released: US$1.09 loss per share (vs US$0.30 loss in 2Q 2020)